Nurexone Biologic Inc

TSXV:NRXCanadaView on OTCQB

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medicines Agency (the "EMA") has granted Orphan Medicinal Product Designation for the Company's ExoPTEN therapy, marking a significant step towards making this potential treatment available for acute spinal cord injury patients across Europe. This designation supports the development of ExoPTEN and opens a pathway for faster entry into European markets, where the Company expects demand for effective spinal cord injury therapies to be high. Designed to provide nerve regeneration and functional recovery following spinal cord injury, ExoPTEN uses mesenchymal stem cell-derived extracellular vesicles loaded with siRNA targeting PTEN, a key protein in nerve regeneration.

These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the general business and economic conditions of the industries and countries in which we operate; the Company's drug products having its intended benefits and effects; the Company's intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company's production methods continuing to be reliable; the Company will have flexibility in optimizing its exosome production method; exosomes will serve as an excellent, targeted system for drug delivery; the Company will pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and with future collaboration partners; the Company's ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; ITG and Oak Hill engagements will not be terminated and each will fulfill their duties under the respective agreements; the engagements will have a positive impact on the Company and its securities; and the NurExone platform technology offering novel solutions to drug companies interested in non-invasive targeted drug delivery for other indications.

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76(th) Emerging Growth Conference on October 30 & 31, 2024.